Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
Open Access
- 26 December 1996
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 335 (26), 1950-1955
- https://doi.org/10.1056/nejm199612263352603
Abstract
Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a phase 3 trial to compare the effects of intraperitoneal and intravenous cisplatin on the survival of women with previously untreated, stage III, epithelial ovarian cancer.Keywords
This publication has 13 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.Journal of Clinical Oncology, 1991
- Effect of Sodium Thiosulfate on the Pharmacokinetics and Toxicity of CisplatinJNCI Journal of the National Cancer Institute, 1989
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.Journal of Clinical Oncology, 1987
- Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.Journal of Clinical Oncology, 1987
- Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavityCancer Treatment Reviews, 1986
- Intraperitoneal Cisplatin with Systemic Thiosulfate ProtectionAnnals of Internal Medicine, 1982